Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer (TREVI-OC-03)

7 september 2026 uppdaterad av: AstraZeneca

A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan With or Without Bevacizumab Versus Standard of Care as Second- or Third-Line Maintenance Treatment in Participants With Platinum-sensitive Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-03)

The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed ovarian cancer (PSR OC)

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

600

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Auchenflower, Australien, 4066
        • Research Site
      • Blacktown, Australien, 2148
        • Research Site
      • Clayton, Australien, 3168
        • Research Site
      • Liverpool, Australien, 2170
        • Research Site
      • Porto Alegre, Brasilien, 90035903
        • Research Site
      • São Caetano do Sul, Brasilien, 09541-270
        • Research Site
      • São José do Rio Preto, Brasilien, 15090-000
        • Research Site
      • São José dos Campos, Brasilien, 12210-030
        • Research Site
      • São Paulo, Brasilien, 01327-001
        • Research Site
      • Teresina, Brasilien, 64049-200
        • Research Site
      • Vitória, Brasilien, 29043-260
        • Research Site
    • Alaska
      • Anchorage, Alaska, Förenta staterna, 99508
        • Research Site
    • Maryland
      • Columbia, Maryland, Förenta staterna, 21044
        • Research Site
    • Michigan
      • Detroit, Michigan, Förenta staterna, 48201
        • Research Site
    • New York
      • Albany, New York, Förenta staterna, 12206
        • Research Site
      • Bay Shore, New York, Förenta staterna, 11706
        • Research Site
      • Greenlawn, New York, Förenta staterna, 11740
        • Research Site
      • New Hyde Park, New York, Förenta staterna, 11042
        • Research Site
      • New York, New York, Förenta staterna, 10029
        • Research Site
      • Rego Park, New York, Förenta staterna, 11374
        • Research Site
    • Ohio
      • Cleveland, Ohio, Förenta staterna, 44195
        • Research Site
      • Cleveland, Ohio, Förenta staterna, 44111
        • Research Site
      • Columbus, Ohio, Förenta staterna, 43210
        • Research Site
      • Mayfield Heights, Ohio, Förenta staterna, 44124
        • Research Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19107
        • Research Site
      • Willow Grove, Pennsylvania, Förenta staterna, 19090
        • Research Site
    • West Virginia
      • Morgantown, West Virginia, Förenta staterna, 26506
        • Research Site
      • Ahmedabad, Indien, 380060
        • Research Site
      • Bangalore, Indien, 560004
        • Research Site
      • Gurgaon, Indien, 122002
        • Research Site
      • Kottayam, Indien, 686008
        • Research Site
      • Madurai, Indien, 625107
        • Research Site
      • Nashik, Indien, 422002
        • Research Site
      • Nashik, Indien, 422 009
        • Research Site
      • New Delhi, Indien, 11029
        • Research Site
      • Vadodara, Indien, 391760
        • Research Site
      • Fukuoka, Japan, 812-8582
        • Research Site
      • Fukushima, Japan, 960-1295
        • Research Site
      • Kobe, Japan, 650-0047
        • Research Site
      • Kyoto, Japan, 612-8555
        • Research Site
      • Kōtoku, Japan, 135-8550
        • Research Site
      • Minatoku, Japan, 105-8471
        • Research Site
      • Natori-shi, Japan, 981-1293
        • Research Site
      • Sagamihara-shi, Japan, 252-0375
        • Research Site
      • Shinjuku-ku, Japan, 160-0023
        • Research Site
      • Suita-shi, Japan, 565-0871
        • Research Site
      • Toyoake-shi, Japan, 470-1192
        • Research Site
      • Yokohama, Japan, 236-0004
        • Research Site
    • British Columbia
      • Abbotsford British Columbia, British Columbia, Kanada, V2S0C2
        • Research Site
    • Quebec
      • Montreal, Quebec, Kanada, H3A 1A1
        • Research Site
      • Montreal, Quebec, Kanada, H2X 0A9
        • Research Site
      • Beijing, Kina, 100210
        • Research Site
      • Guangdong Province, Kina, 510060
        • Research Site
      • Guangzhou, Kina, 510060
        • Research Site
      • Wuhan, Kina, 430030
        • Research Site
      • Goyang-si, Sydkorea, 10408
        • Research Site
      • Seoul, Sydkorea, 03080
        • Research Site
      • Seoul, Sydkorea, 03722
        • Research Site
      • Seoul, Sydkorea, 135-710
        • Research Site
      • Seoul, Sydkorea, 5505
        • Research Site
      • Kaohsiung City, Taiwan, 81362
        • Research Site
      • Taichung, Taiwan, 40705
        • Research Site
      • Taichung, Taiwan, 40447
        • Research Site
      • Tainan, Taiwan, 70403
        • Research Site
      • Taipei, Taiwan, 10449
        • Research Site
      • Bangkok, Thailand, 10210
        • Research Site
      • Bangkok, Thailand, 10330
        • Research Site
      • Bangkok, Thailand, 10700
        • Research Site
      • Hat Yai, Thailand, 90110
        • Research Site
      • Muang, Thailand, 50200
        • Research Site
      • Bad Homburg, Tyskland, 61352
        • Research Site
      • Bonn, Tyskland, 53127
        • Research Site
      • Brandenburg, Tyskland, 14770
        • Research Site
      • Gütersloh, Tyskland, 33332
        • Research Site
      • Homburg, Tyskland, 66421
        • Research Site
      • Kassel, Tyskland, 34125
        • Research Site
      • Mainz, Tyskland, 55131
        • Research Site
      • Mannheim, Tyskland, 68167
        • Research Site
      • Wiesbaden, Tyskland, 65189
        • Research Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Participants with confirmed histology of high-grade epithelial serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer.
  • Provision of an archival FFPE tumour sample
  • Participants who received at least one, and no more than 2 lines of prior systemic anticancer therapy.
  • Participants with radiologically confirmed disease relapse ≥ 6 months after their last platinum chemotherapy infusion in the previous line of treatment
  • Participants who received at least 6 cycles of PBC during the induction phase of their current line of treatment.
  • Participants assigned to bevacizumab must have received a minimum of 3 cycles of bevacizumab with 3 cycles of PBC prior to randomisation.
  • Participants with non-progressive disease upon completion of PBC in their current line of treatment.
  • Participants with documented BRCA mutation 1/2 must have received prior PARP inhibitor (unless ineligible due to contraindications, precautions, or intolerance).

Exclusion Criteria:

  • Participants with tumours of non-epithelial origin, borderline tumours, clear cell OC, mucinous OC, carcinosarcoma, or low-grade epithelial tumours.
  • Participants with history of (non-infectious) ILD/pneumonitis that required steroids, or supplemental oxygen, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening
  • Participants with non-healing wound, active ulcer, or bone fracture (not applicable if not receiving bevacizumab)
  • Participants with evidence of active or ongoing bowel obstruction (not applicable if not receiving bevacizumab)
  • Participants with prior exposure to any FRα-targeted therapy, including MIRV, or any TOP1i Antibody-drug Conjugate (ADC)

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Torvutatug samrotecan monotherapy or in combination with bevacizumab
Torvutatug samrotecan monotherapy intravenous (IV) or Torvutatug samrotecan IV with bevacizumab IV.
FRa targeting antibody drug conjugate Topoisomerase I inhibitor
Andra namn:
  • AZD5335
Monoclonal antibody inhibitor of Vascular Endothelial Growth Factor
Aktiv komparator: Observation or bevacizumab
Observation or bevacizumab IV.
Monoclonal antibody inhibitor of Vascular Endothelial Growth Factor

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Progression-Free Survival (PFS)
Tidsram: Up to approximately 5 years
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by Blinded Independent Central Review, or death due to any cause.
Up to approximately 5 years

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overall Survival (OS)
Tidsram: Up to approximately 5 years
OS is defined as time from randomisation until the date of death due to any cause.
Up to approximately 5 years
Second Progression-Free Survival (PFS2)
Tidsram: Up to approximately 5 years
PFS2 is defined as time from randomisation to the earliest of the progression event (following the initial investigator-assessed progression) after first subsequent therapy, or death.
Up to approximately 5 years
Time to First Subsequent Therapy (TFST)
Tidsram: Up to approximately 5 years
TFST is defined as time from randomisation until the start date of the first subsequent anti-cancer therapy after discontinuation of randomised treatment, or death due to any cause.
Up to approximately 5 years
Time to Second Subsequent Therapy (TSST)
Tidsram: Up to approximately 5 years
TSST is defined as time from randomisation until the start date of the second subsequent anti-cancer therapy after discontinuation of randomised treatment, or death due to any cause.
Up to approximately 5 years
Health-related Quality of Life (HrQoL)
Tidsram: Up to approximately 5 years
Change from baseline and time to deterioration in global health status/quality of life (GHS/QoL), physical functioning (PF), and ovarian cancer symptoms (EORTC IL433).
Up to approximately 5 years
Number and percentage of participants with adverse events as graded by CTCAE v6 criteria
Tidsram: Up to approximately 5 years
Adverse Event Incidence
Up to approximately 5 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

29 september 2026

Primärt slutförande (Beräknad)

26 september 2028

Avslutad studie (Beräknad)

27 oktober 2031

Studieregistreringsdatum

Först inskickad

7 september 2026

Först inskickad som uppfyllde QC-kriterierna

7 september 2026

Första postat (Faktisk)

14 september 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

14 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

7 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Tidsram för IPD-delning

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Kriterier för IPD Sharing Access

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera